remogliflozin etabonate (BioDeep_00000837820)
代谢物信息卡片
remogliflozin etabonate
化学式: C26H38N2O9 (522.2577178)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC(=O)OCC1C(C(C(C(O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
InChI: InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:177541
- KEGGdrug: D10055
- PubChem: 9871420
- DrugBank: DB12935
- ChEMBL: CHEMBL2028665
- CAS: 442201-24-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Kiran Khaladkar, Brij Mohan, Kiran Khaladkar, Sachin Suryawanshi, Hanmant Barkatestrong/Strong. Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
The Journal of the Association of Physicians of India.
2022 Apr; 70(4):11-12. doi:
NULL. [PMID: 35443373] - Robert Dobbins, Elizabeth K Hussey, Robin O'Connor-Semmes, Susan Andrews, Wenli Tao, William O Wilkison, Bentley Cheatham, Katare Sagar, Barkate Hanmant. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
BMC pharmacology & toxicology.
2021 06; 22(1):34. doi:
10.1186/s40360-021-00502-0. [PMID: 34120651] - Kazuo Shimizu, Hideki Fujikura, Nobuhiko Fushimi, Toshihiro Nishimura, Kazuya Tatani, Kenji Katsuno, Yoshikazu Fujimori, Shinjiro Watanabe, Masahiro Hiratochi, Takeshi Nakabayashi, Noboru Kamada, Koichi Arakawa, Hidemasa Hikawa, Isao Azumaya, Masayuki Isaji. Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
Bioorganic & medicinal chemistry.
2021 03; 34(?):116033. doi:
10.1016/j.bmc.2021.116033. [PMID: 33581390] - Mala Dharmalingam, S R Aravind, Hemant Thacker, S Paramesh, Brij Mohan, Manoj Chawla, Arthur Asirvatham, Ramesh Goyal, Jayashri Shembalkar, R Balamurugan, Pradnya Kadam, Hansraj Alva, Rahul Kodgule, Monika Tandon, Sivakumar Vaidyanathan, Amol Pendse, Rajesh Gaikwad, Sagar Katare, Sachin Suryawanshi, Hanmant Barkate. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Drugs.
2020 Apr; 80(6):587-600. doi:
10.1007/s40265-020-01285-0. [PMID: 32162274] - Shashank Joshi, Girish Gudi, Vinu C A Menon, Monika Tandon, Vikas Joshi, Sachin Suryawanshi, Hanmant Barkate, Nikhil Sawant, Sagar Katare, Waseem Siddique. An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions.
Clinical pharmacokinetics.
2020 03; 59(3):349-357. doi:
10.1007/s40262-019-00819-4. [PMID: 31583610] - Robin O'Connor-Semmes, Susan Walker, Anita Kapur, Elizabeth K Hussey, June Ye, Laurene Wang-Smith, Wenli Tao, Robert L Dobbins, Bentley Cheatham, William O Wilkison. Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
Drug metabolism and disposition: the biological fate of chemicals.
2015 Jul; 43(7):1077-83. doi:
10.1124/dmd.114.062828. [PMID: 25934577] - A P Sykes, G L Kemp, R Dobbins, R O'Connor-Semmes, S R Almond, W O Wilkison, S Walker, L Kler. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Diabetes, obesity & metabolism.
2015 Jan; 17(1):98-101. doi:
10.1111/dom.12393. [PMID: 25238025] - Nasser Mikhail. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Expert opinion on investigational drugs.
2015; 24(10):1381-7. doi:
10.1517/13543784.2015.1061501. [PMID: 26288025] - A P Sykes, R O'Connor-Semmes, R Dobbins, D J Dorey, J D Lorimer, S Walker, W O Wilkison, L Kler. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Diabetes, obesity & metabolism.
2015 Jan; 17(1):94-7. doi:
10.1111/dom.12391. [PMID: 25223369] - Anita Kapur, Robin O'Connor-Semmes, Elizabeth K Hussey, Robert L Dobbins, Wenli Tao, Marcus Hompesch, Glenn A Smith, Joseph W Polli, Charles D James, Imao Mikoshiba, Derek J Nunez. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
BMC pharmacology & toxicology.
2013 May; 14(?):26. doi:
10.1186/2050-6511-14-26. [PMID: 23668634] - Elizabeth K Hussey, Anita Kapur, Robin O'Connor-Semmes, Wenli Tao, Bryan Rafferty, Joseph W Polli, Charles D James, Robert L Dobbins. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
BMC pharmacology & toxicology.
2013 Apr; 14(?):25. doi:
10.1186/2050-6511-14-25. [PMID: 23631443] - Robin L O'Connor-Semmes, Erik P Sandefer, Elizabeth K Hussey, Wenli Tao, Walter J Doll, Richard C Page, Robert Dobbins. Regional gastrointestinal delivery of remogliflozin etabonate in humans.
Biopharmaceutics & drug disposition.
2013 Mar; 34(2):79-86. doi:
10.1002/bdd.1824. [PMID: 23111980] - James F Sigafoos, Gary D Bowers, Stephen Castellino, Amanda G Culp, David S Wagner, Melinda J Reese, Joan E Humphreys, Elizabeth K Hussey, Robin L O'Connor Semmes, Anita Kapur, Wenli Tao, Robert L Dobbins, Joseph W Polli. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Nov; 40(11):2090-101. doi:
10.1124/dmd.112.047258. [PMID: 22851617] - Sunder Mudaliar, Debra A Armstrong, Annie A Mavian, Robin O'Connor-Semmes, Patricia K Mydlow, June Ye, Elizabeth K Hussey, Derek J Nunez, Robert R Henry, Robert L Dobbins. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Diabetes care.
2012 Nov; 35(11):2198-200. doi:
10.2337/dc12-0508. [PMID: 23011728] - R L Dobbins, R O'Connor-Semmes, A Kapur, C Kapitza, G Golor, I Mikoshiba, W Tao, E K Hussey. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
Diabetes, obesity & metabolism.
2012 Jan; 14(1):15-22. doi:
10.1111/j.1463-1326.2011.01462.x. [PMID: 21733056] - Chun-Hsu Yao, Jen-Shin Song, Chiung-Tong Chen, Teng-Kuang Yeh, Ming-Shiu Hung, Chih-Chun Chang, Yu-Wei Liu, Mao-Chia Yuan, Chieh-Jui Hsieh, Chung-Yu Huang, Min-Hsien Wang, Ching-Hui Chiu, Tsung-Chih Hsieh, Szu-Huei Wu, Wen-Chi Hsiao, Kuang-Feng Chu, Chi-Hui Tsai, Yu-Sheng Chao, Jinq-Chyi Lee. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Journal of medicinal chemistry.
2011 Jan; 54(1):166-78. doi:
10.1021/jm101072y. [PMID: 21128592] - William N Washburn. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Journal of medicinal chemistry.
2009 Apr; 52(7):1785-94. doi:
10.1021/jm8013019. [PMID: 19243175] - Yoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima, Yukiko Ishikawa-Takemura, Hideki Fujikura, Masayuki Isaji. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
The Journal of pharmacology and experimental therapeutics.
2008 Oct; 327(1):268-76. doi:
10.1124/jpet.108.140210. [PMID: 18583547]